<DOC>
	<DOCNO>NCT00255476</DOCNO>
	<brief_summary>The purpose study compare objectie tumour response rate cisplatin/5FU cisplatin/5FU plus ZD1839 combination</brief_summary>
	<brief_title>The IRESSA Novel Head Neck Chemotherapy Evaluation Study</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms , Squamous Cell</mesh_term>
	<mesh_term>Carcinoma , Squamous Cell</mesh_term>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Gefitinib</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>Provision write informed consent Patients histologically proven primary SCCHN Aged 18 Patients eligible surgery curative intent Other coexist malignancy diagnose within last 5 year exception basal cell carcinoma cervical cancer situ Exclude UCNT</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2009</verification_date>
</DOC>